title: Regional resistance surveillance program results for 12 Asia-Pacific nations (2011).
abstract: The Regional Resistance Surveillance program monitored susceptibility rates and developing resistance by geographic region, including 12 Asia-Pacific (APAC) countries. Reference broth microdilution methods for susceptibility/interpretations were applied, processing 5,053 strains. Among Staphylococcus aureus isolates (37% methicillin-resistant S. aureus [MRSA], highest in South Korea [73%]), linezolid (LZD), tigecycline (TIG), and vancomycin were 100% active, but 33 and 34% of strains were levofloxacin (LEV) or macrolide resistant, respectively. Streptococcus pneumoniae was most resistant to β-lactams and macrolides (45%) but was LZD, LEV, and TIG susceptible (>98%). Extended-spectrum β-lactamase (ESBL) phenotype rates in Escherichia coli and Klebsiella spp. were 48 and 47%, respectively, and were highest in Taiwan, at 75 to 91%. The best anti-ESBL-phenotype agents were amikacin (81 to 96% susceptible), colistin (COL; >98%), TIG (>98%), and carbapenems (81 to 97%). Pseudomonas aeruginosa showed ≥20% resistance to all drugs except COL (99% susceptible). In conclusion, endemic evolving antimicrobial resistances in APAC nations show compromised roles for many commonly used antimicrobials.
authors: JMI Laboratories, North Liberty, Iowa, USA.
authors: Rodrigo E
authors: RE
authors: Mendes
authors: Myrna
authors: M
authors: Mendoza
authors: Kirnpal K
authors: KK
authors: Banga Singh
authors: Mariana
authors: M
authors: Castanheira
authors: Jan M
authors: JM
authors: Bell
authors: John D
authors: JD
authors: Turnidge
authors: Stephen S F
authors: SS
authors: Lin
authors: Ronald N
authors: RN
authors: Jones
mesh_terms: D000900:Anti-Bacterial Agents / Q000145:classification / Q000627:therapeutic use*; D001208:Asia / Q000453:epidemiology; D001315:Australia / Q000453:epidemiology; D024901:Drug Resistance, Multiple, Bacterial; D062665:Epidemiological Monitoring; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D007709:Klebsiella / Q000187:drug effects / Q000254:growth & development; D008826:Microbial Sensitivity Tests; D009520:New Zealand / Q000453:epidemiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000254:growth & development; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000254:growth & development
chemical_list: D000900:Anti-Bacterial Agents
references: J Antimicrob Chemother. 2011 May;66 Suppl 4:iv17-iv21
references: 21521703
references: Antimicrob Agents Chemother. 2008 Feb;52(2):570-3
references: 18070960
references: Int J Antimicrob Agents. 2012 Jun;39(6):490-5
references: 22534507
references: Antimicrob Agents Chemother. 2004 Jan;48(1):1-14
references: 14693512
references: Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60
references: 21859938
references: Diagn Microbiol Infect Dis. 2013 Nov;77(3):258-66
references: 24055218
references: Microb Drug Resist. 2009 Dec;15(4):245-9
references: 19857129
references: J Infect. 2009 Sep;59 Suppl 1:S4-16
references: 19766888
references: J Infect. 2010 Jun;60(6):440-51
references: 20361999
references: Lancet Infect Dis. 2010 Sep;10(9):597-602
references: 20705517
references: Clin Microbiol Infect. 2010 Dec;16(12):1699-701
references: 20874758
references: J Antimicrob Chemother. 2003 Feb;51(2):339-45
references: 12562700
references: Diagn Microbiol Infect Dis. 2013 Jun;76(2):206-13
references: 23478031
references: J Antimicrob Chemother. 2011 Jun;66(6):1409-11
references: 21421581
references: Mayo Clin Proc. 2012 Feb;87(2):198-208
references: 22305032